The abstract is read at the publisher; the summary is JClub's.
A risk-model-agnostic framework for US women maps absolute breast cancer risk cut points to screening intervals, producing a risk-scaled gradient (annual at 2%-3%, annual with supplemental imaging/counseling at ≥3%).
- Why it matters: Precision mammography trials currently use mismatched risk models, risk strata, and screening intervals, with no agreed method to translate absolute risk into screening frequency.
- What they did: The authors developed and evaluated a framework that converts guideline-defined absolute-risk cut points into screening intervals, then compared its interval assignments with those used in ongoing intervention trials.
- The result: Trial-assigned screening intervals varied widely and were not uniformly aligned with absolute-risk levels, while the framework provides a transparent, standardized mapping to guide future personalized screening design and routine practice.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.